API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The approval of Sucralfate Oral Suspension, through initial development of twelve different bioassays that tracked product's postulated clinical interactions using in vitro biology, marks a paradigm shift in how complex generic drug products can be commercialized.
Lead Product(s): Sucralfate
Therapeutic Area: Gastroenterology Product Name: Sucralfate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: VistaPharm, Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022